Sellas Life Sciences is trading at $9.87, down 12.96%, amid investor caution ahead of the high-risk Phase 3 REGAL readout and concerns over delayed results.
- No new company-specific announcement was identified for October 16.
- XBI is down 2.06% during the regular session as the biotech sector faces pressure.
- The decline follows consecutive losses in the provided price history; no trading-volume figure was available.